[Gliflozins和finerenone:它们的组合有什么前景?]
Jean-Christophe Philips1, Régis P Radermecker1,2
1Service de diabétologie, nutrition et maladies métaboliques, CHU Sart-Tilman, 4000 Liège, Belgique.
Revue medicale suisse
|August 23, 2023
概括
糖尿病病增加了心血管疾病的风险. 结合SGLT2抑制剂 (gliflozins) 和finerenone,为患有慢性病的患者提供了有前途的心保护.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病病 (DKD) 是糖尿病的一个主要并发症,导致功能逐渐下降.
- 脏恶化增加了心血管疾病的风险,并在末期脏疾病中需要昂贵的透析.
- 目前对DKD的治疗方法存在局限性,这凸显了对新型治疗策略的需求.
研究的目的:
- 探索结合SGLT2抑制剂 (gliflozins) 和finerenone在糖尿病患者心脏脏保护方面的潜在益处.
- 根据现有数据和机理见解,评估这两个不同的药理类的协同效应.
主要方法:
- 审查当前的科学文献和探索性分析.
- 考虑SGLT2抑制剂和finerenone的不同作用机制.
- 基于临床前和临床观察的潜在组合疗法的评估.
主要成果:
- SGLT2 抑制剂和菲内伦已经独立地证明了显著的心脏脏保护作用.
- 它们的不同作用机制表明它们在治疗糖尿病病方面起着互补的作用.
- 探索性数据表明,组合治疗的前景充满希望.
结论:
- 结合SGLT2抑制剂 (gliflozins) 和finerenone是一种有前途的治疗策略,用于管理糖尿病病.
- 与单一治疗相比,这种组合可能会提供更好的心脏脏保护.
- 需要进一步的临床研究来证实这种综合方法的疗效和安全性.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
01:06Oral Hypoglycemic Agents: Glinides
184
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184
01:24Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
01:17Oral Hypoglycemic Agents: Sulfonylureas
236
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
236
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13